MAGNESIUM SULFATE IN PLASTIC CONTAINER
Clinical safety rating
cautionComprehensive clinical and safety monograph for MAGNESIUM SULFATE IN PLASTIC CONTAINER (MAGNESIUM SULFATE IN PLASTIC CONTAINER).
Magnesium sulfate causes decreased release of acetylcholine at the neuromuscular junction, reducing muscle contractility. It also blocks calcium channels, leading to vasodilation and anticonvulsant effects.
| Metabolism | Magnesium sulfate is primarily excreted unchanged by the kidneys. It does not undergo significant hepatic metabolism. |
| Excretion | Primarily renal (glomerular filtration); >90% excreted unchanged in urine. Biliary/fecal elimination is negligible (<1%). |
| Half-life | Normal renal function: 4–6 hours (terminal). In oliguria or anuria, half-life may extend to >24 hours, requiring dose adjustment. |
| Protein binding | Approximately 30–40% bound to albumin. |
| Volume of Distribution | 0.2–0.3 L/kg. Distributes mainly in extracellular fluid; crosses placenta and blood-brain barrier. |
| Bioavailability | IV: 100%. IM: ~80% (variable). Oral: <20% (poor, due to limited absorption; primarily used for catharsis). |
| Onset of Action | IV: Immediate (1–2 minutes). IM: 30–60 minutes. Oral: Not relevant for systemic effects (2–4 hours for catharsis). |
| Duration of Action | IV: 30 minutes (anticonvulsant). IM: 3–4 hours. Continuous IV infusion maintains effect. Oral: 3–6 hours (cathartic). |
| Molecular Weight | 120.37 |
IV: 1-4 g as a 10-20% solution, rate not exceeding 1 g/min; for eclampsia: 4-5 g IV bolus then 1-2 g/hour IV infusion.
| Dosage form | INJECTABLE |
| Renal impairment | GFR <20 mL/min: maximum dose 2 g; avoid use if anuria. GFR 20-50 mL/min: reduce dose by 25-50%. |
| Liver impairment | Child-Pugh Class B or C: reduce dose by 50% and monitor serum magnesium levels. |
| Pediatric use | IV: 20-40 mg/kg/dose (max 2 g) as 10% solution; for severe hypomagnesemia: 25-50 mg/kg/dose q4-6h. |
| Geriatric use | Reduce initial dose by 25-50%; infuse over longer period; monitor renal function and serum magnesium closely. |
| 1st trimester | Magnesium sulfate crosses the placenta and is associated with an increased risk of congenital malformations (e.g., skeletal anomalies) when used in the first trimester. Use only if clearly needed for conditions such as severe preeclampsia/eclampsia. |
| 2nd trimester | Similar risks to t1; avoid prolonged use. Short-term use for seizure prophylaxis may be considered if benefits outweigh risks. Monitor for fetal effects such as hypotonia and respiratory depression. |
| 3rd trimester | Safety concerns include neonatal hypermagnesemia, hypotonia, respiratory depression, and hypocalcemia if administered near delivery. Use only for seizure prophylaxis in preeclampsia/eclampsia. Prolonged use (e.g., tocolysis) is not recommended due to fetal harm. |
Clinical note
Comprehensive clinical and safety monograph for MAGNESIUM SULFATE IN PLASTIC CONTAINER (MAGNESIUM SULFATE IN PLASTIC CONTAINER).
| Placental transfer | Magnesium sulfate readily crosses the placenta. Fetal serum concentrations reach 80-100% of maternal levels within 2-3 hours of continuous infusion. Transfer is primarily by passive diffusion. |
| Breastfeeding | Magnesium sulfate is excreted into breast milk in low concentrations. Short-term use is generally considered compatible with breastfeeding. Monitor infant for signs of hypermagnesemia (e.g., hypotonia, drowsiness). Avoid high-dose or prolonged therapy. |
| Lactation Rating | L2 (Safer if used cautiously, limited data suggest low risk). |
| Teratogenic Risk | Prolonged use (≥5-7 days) in pregnancy is associated with fetal hypocalcemia, skeletal demineralization, and neonatal hypermagnesemia. No increased risk of major malformations with standard short-term use. Third trimester: risk of neonatal hypotonia, respiratory depression if given near delivery. Continuous infusion for tocolysis >48 hours increases risk of neonatal bone abnormalities. |
| Fetal Monitoring | Monitor maternal deep tendon reflexes, respiratory rate (≥16/min), urine output (≥100 mL/4h), serum magnesium levels (therapeutic range 4-7 mEq/L). Fetal: continuous fetal heart rate monitoring during parenteral administration. Neonatal: assess for hypotonia, respiratory effort, and serum magnesium if indicated. |
| Fertility Effects | No known adverse effects on fertility. Magnesium is an essential cation; deficiency may impair ovulation. No evidence of reproductive toxicity at therapeutic doses. |
■ FDA Black Box Warning
Continuous infusion of magnesium sulfate can cause hypermagnesemia, which may lead to respiratory depression or cardiac arrest. Only use with continuous monitoring of serum magnesium levels and clinical status.
| Serious Effects |
Hypersensitivity to magnesium sulfate or any componentHeart block or myocardial damageSevere renal impairment (creatinine clearance <20 mL/min) without ability to monitor serum magnesium levelsHypermagnesemia (serum magnesium >2.5 mEq/L)
| Precautions | Risk of hypermagnesemia, especially in renal impairment; monitor serum magnesium levels, deep tendon reflexes, and respiratory rate; use with caution in patients with myasthenia gravis or heart block; avoid extravasation due to risk of tissue necrosis. |
| Food/Dietary | No specific food interactions. However, high dietary magnesium intake from supplements or foods may increase risk of toxicity when receiving magnesium sulfate. Maintain adequate hydration. |
| Clinical Pearls | Magnesium sulfate is first-line for eclampsia and severe preeclampsia. Monitor for loss of deep tendon reflexes (DTRs) as early sign of toxicity; DTRs disappear at ~10 mEq/L serum magnesium. Calcium gluconate is the antidote for magnesium toxicity. Use with caution in renal impairment; dose adjustment recommended. IV administration can cause hypotension and bradycardia. Not compatible with solutions containing calcium; may precipitate. |
| Patient Advice | Report any muscle weakness, difficulty breathing, or extreme drowsiness immediately. · You may experience warmth, flushing, or sweating during IV infusion. · Avoid driving or operating heavy machinery until effects are known. · Inform your doctor if you have kidney disease, heart block, or are taking other medications. · Use during pregnancy is typically under close monitoring; discuss risks and benefits. · Do not suddenly stop taking magnesium sulfate; follow prescribed tapering schedule. |
Loading safety data…